Systemic 5-fluorouracil producing an inflammatory response in porokeratosis

Journal of the European Academy of Dermatology and Venereology

Volumn 17, Issue 2, 2003, Pages 190-192

  Nahm, W K ^a   Donohue, K G ^a   Danahy, J F ^a   Badiavas, E ^a   Falanga, V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 fluorouracil; Actinic keratosis; Chemotherapy; Porokeratosis

Indexed keywords

DIPHENHYDRAMINE; FLUOROURACIL; TRIAMCINOLONE ACETONIDE;

ACTINIC POROKERATOSIS; AGED; ARTICLE; BREAST CANCER; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; METASTASIS; PATIENT ATTITUDE; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN EXAMINATION; SKIN INFLAMMATION; SYMPTOM; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; POROKERATOSIS;

EID: 0037357682     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-3083.2003.00575.x     Document Type: Article

References (19)

1. Omura EF, Torre D. Inflammation of actinic keratoses due to systemic fluorouracil therapy. JAMA 1969; 208: 150-151.
2. Nabai H, Mohindra R, Mehregan D. Selective inflammatory effect of systemic fluorouracil in actinic keratosis. Cutis 1999; 64: 43-44.
3. Sander CA, Pfeiffer C, Kligman AM, Plewig G. Chemotherapy for disseminated actinic keratoses with 5-fluorouracil and isotretinoin. J Am Acad Dermatol 1997; 36: 236-238.
4. Shelley WB, Shelley ED. Disseminated superficial porokeratosis: rapid therapeutic response to 5- fluorouracil. Cutis 1983; 32: 139-140.
5. Balato N, Di Nardo G, Boccia L, Nappa P. Linear Mibelli's porokeratosis. Treatment with topical 5-fluorouracil. G Ital Dermatol Venereol 1986; 121: 147-148.
6. Goodman LS, Gilman A, Hardman JG, Gilman AG, Limbird LE. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill Health Professions Division, New York, 1996.
7. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16: 301-308.
8. Kennedy BJ, Theologides A. The role of 5-fluorouracil in malignant disease. Ann Intern Med 1961; 55: 719.
9. Fitzpatrick JE, Yokel BE, Hood AF. Mucocutaneous Complications of Antineoplastic Therapy. In: Freedberg IM, Eisen AZ, Wolff K et al. editors. Fitzpatrick's Dermatology in General Medicine, 5th ed. McGraw-Hill Health Professions Division, New York, 1999, 1642-1653.
10. Chernosky ME. Porokeratosis. Arch Dermatol 1986; 122: 869-870.
11. Wade TR, Ackerman AB. Cornoid lamellation. A histologic reaction pattern. Am J Dermatopathol 1980; 2: 5-15.
12. Reed RJ, Leone P. Porokeratosis - a mutant clonal keratosis of the epidermis. I. Histogenesis. Arch Dermatol 1970; 101: 340-347.
13. Chernosky ME, Anderson DE. Disseminated superficial actinic porokeratosis. Clinical studies and experimental production of lesions. Arch Dermatol 1969; 99: 401-407.
14. Anderson DE, Chernosky ME. Disseminated superficial actinic porokeratosis. Genetic aspects. Arch Dermatol 1969; 99: 408-412.
15. Bencini PL, Tarantino A, Grimalt R, Ponticelli C, Caputo R. Porokeratosis and immunosuppression. Br J Dermatol 1995; 132: 74-78.
16. Herranz P, Pizarro A, De Lucas R et al. High incidence of porokeratosis in renal transplant recipients. Br J Dermatol 1997; 136: 176-179.
17. O'Donnell BP, Dawson NA, Weiss RB, Myers CE, James WD. Suramin-induced skin reactions. Arch Dermatol 1992; 128: 75-79.
18. Murata Y, Kumano K, Takai T. Type 2 segmental manifestation of disseminated superficial porokeratosis showing a systematized pattern of involvement and pronounced cancer proneness. Eur J Dermatol 2001; 11: 191-194.
19. Falkson G, Schulz EZ. Skin changes in patients treated with 5-fluorouracil. Br J Dermatol 1962; 74: 229.